Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
A Closer Look at IL-17 Inhibitors in Psoriasis : Episode 8
Opinion
Video
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumab’s 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use. Bimekizumab’s 4-year data (Blauvelt, 2024; Gordon, 2024) demonstrate continued efficacy, with 5-year results anticipated at AAD 2025.
Video content above is prompted by the following:
- What do we know about the long-term safety and efficacy of IL-17 inhibitors in psoriasis?
- Secukinumab 5-year data (Bissonnette, 2018; Langley, 2022)
- Ixekizumab 5-year data (Blauvelt, 2021)
- Brodalumab 5-year pharmacovigilance (Lebwohl, 2024); 120-week data (Puig, 2020)
- Bimekizumab 4-year data (Blauvelt, 2024; Gordon, 2024); 5-year data expected at AAD 2025
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
